Advertisement

Current HIV/AIDS Reports

, Volume 11, Issue 3, pp 195–201 | Cite as

Understanding the Etiology and Management of HIV-Associated Peripheral Neuropathy

  • Kara Stavros
  • David M. Simpson
Complications of Antiretroviral Therapy (JM Kilby, Section Editor)

Abstract

HIV may cause several forms of peripheral neuropathy, the most common of which is distal symmetric polyneuropathy (DSP) characterized by pain and sensory deficits in a stocking-glove distribution. The pathophysiology of DSP remains largely unknown but is thought to be related both to the neurotoxicity of HIV—through indirect immunomodulatory mechanisms—and to the neurotoxic effects of anti-retroviral therapies, most notably the dideoxynucleoside reverse transcription inhibitors or so-called d-drugs. Determining whether symptoms arise from the virus or the treatment poses a challenge to the clinician who must decide if a patient’s HAART regimen should be altered. Treatment of symptoms related to HIV-DSP is a difficult task and there is no evidence that the traditional agents used in chronic neuropathic pain are efficacious in the HIV-DSP population. Indeed few pharmacologic agents have proven efficacy in HIV-DSP – these include cannabis and the capsaicin 8 % dermal patch. As such, alternative, non-pharmacologic therapies are being investigated. More research is needed to further elucidate the complex pathophysiology of HIV-DSP which may yield additional therapies for these patients.

Keywords

HIV Peripheral neuropathy Distal symmetric polyneuropathy, DSP Anti-retroviral Pain 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Kara Stavros declares that she has no conflict of interest.

David M. Simpson reports personal fees from Astellas, Acorda, Pfizer, Depomed, grants from Astellas, Pfizer, and outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Estanislao LB, Morgello S, Simpson DM. Peripheral neuropathies associated with HIV and hepatitis C co-infection: a review. AIDS. 2005;19 suppl 3:S135–9.PubMedCrossRefGoogle Scholar
  2. 2.••
    Robinson-Papp J, Sharma S, Simpson DM, et al. Autonomic dysfunction is common in HIV and associated with distal symmetric polyneuropathy. J Neurovirol. 2013;19:172–80. Demonstrates that autonomic dysfunction is a common neurologic complication of HIV and finds an association between DSP and autonomic dysfunction.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Pettersen JA, Jones G, Worthington C, et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency sydrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol. 2006;59(5):816–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Evans SR, Ellis RJ, Chen H, et al. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS. 2011;25(7):919–28.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Schiffito G, McDermont MP, McArthur JC, et al. Incidence and risk factors for HIV-associated distal sensory polyneuropathy. Neurology. 2002;58(12):1764–8.CrossRefGoogle Scholar
  6. 6.
    Simpson DM, Kitch D, Evans SR, et al. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology. 2006;66(11):1679–87.PubMedCrossRefGoogle Scholar
  7. 7.
    Morgello S, Estanislao L, Simpson D, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy. Arch Neurol. 2004;61:546–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Robinson-Papp J, Gonzalez-Duarte A, Simpson DM, et al. The roles of ethnicity and antiretroviral in HIV-associated polyneuropathy: a pilot study. J Acquir Immune Defic Syndr. 2009;51(5):569–73.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Chen H, Deng L, et al. Peripheral neuropathy in ART-experienced patients: prevalence and risk factors. J Neurovirol. 2013;19:557–64.PubMedCrossRefGoogle Scholar
  10. 10.
    Pardo CA, McArthur JC, Griffin JW. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst. 2001;6(1):21–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Hao S. The molecular and pharmacological mechanisms and HIV-related neuropathic pain. Curr Neuropharmacol. 2013;11(5):499–512.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Keswani SC, Polley M, Pardo CA, et al. Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol. 2003;54(3):287–96.PubMedCrossRefGoogle Scholar
  13. 13.
    Pinti M, Salomoni P, Coassarizza A. Anti-HIV drugs and the mitochondria. Biochim Biophys Acta. 2006;1757(5–6):700–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9(2):153–61.PubMedGoogle Scholar
  15. 15.
    Brinkman K, ter Hofstede HJ, Burger DM. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12(14):1735–44.PubMedCrossRefGoogle Scholar
  16. 16.
    Lehmann HC, Chen W, Borzan J, et al. Mitochondrial dysfunction in distal axons contributes to human immunodeficiency virus sensory neuropathy. Ann Neurol. 2011;69(1):100–10.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Estanislao LB, Thomas D, Simpson D. HIV neuromuscular disease and mitochondrial function. Mitochondrion. 2004;4(2–3):131–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Huang W, Calvo M, Karu K, et al. A clinically relevant rodent model of the HIV antiretroviral drug stavudine induced painful peripheral neuropathy. Pain. 2013;154:560–75.PubMedCrossRefGoogle Scholar
  19. 19.
    WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2013.Google Scholar
  20. 20.
    WHO. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2014.Google Scholar
  21. 21.
    Panel on antiretroviral guidelines for adults and adolescents, Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, Department of Health and Human Services (DHHS). 2013.Google Scholar
  22. 22.
    Ellis RJ, Marquie-Beck J, Delaney P, et al. Human immunodeficiency virus protease inhibitors and the risk for peripheral neuropathy. Ann Neurol. 2008;64:566–72.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Kokotis P, Schmelz M, Papdimas GK, et al. Polyneuropathy induced by HIV disease and antiretroviral therapy. Clin Neurophysiol. 2013;124:176–82.PubMedCrossRefGoogle Scholar
  24. 24.••
    Keltner JR, Fennema-Notestine C, Vaida F, et al. HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter. J Neurovirol. 2014. doi: 10.1007/s13365-014-0236-8. An observation cohort study that provides interesting new results indicating a pattern of brain parenchymal changes seen in patients with HIV-DSP, which may shed further light on the role of central mechanisms in this disease.PubMedGoogle Scholar
  25. 25.
    Polydefkis M, Yiannoutsos CT, Cohen BA, et al. Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy. Neurology. 2002;58(1):115–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Skopelitis E, Aroni K, Kontos AN, et al. Early detection of subclinical HIV sensory polyneuropathy using intraepidermal nerve fiber density quantification: association with HIV state and surrogate markers. Int J STD AIDS. 2007;18:856.PubMedCrossRefGoogle Scholar
  27. 27.
    Phillips TJC, Cherry CL, Cox S, et al. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2010;5(12):e14433.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Anastasi JK, Capili B, McMahon DJ, et al. Acu/moxa for distal sensory peripheral neuropathy in HIV: a randomized control pilot study. J Assoc Nurses AIDS Care. 2013;24(3):268–75.PubMedCrossRefGoogle Scholar
  29. 29.
    Shlay JC, Chaloner K, Max MB, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy. JAMA. 1998;280(18):1590–5.PubMedCrossRefGoogle Scholar
  30. 30.•
    Dorfman D, George MC, Schnur J, et al. Hypnosis for treatment of HIV neuropathic pain: a preliminary report. Pain Med. 2013;14:1048–56. Provides preliminary results for an effective, non-pharmacologic intervention for reducing pain in HIV-DSP which may be grounds for further research.PubMedCrossRefGoogle Scholar
  31. 31.
    Sandoval R, Roddey T, Giordano P, et al. Randomized trial of lower extremity splinting to manage neuropathic pain and sleep disturbances in people living with HIV/AIDS. J Int Assoc Provid AIDS Care. 2013.Google Scholar
  32. 32.
    Simpson DM, Brown S, Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70(24):2305–13.PubMedCrossRefGoogle Scholar
  33. 33.
    Simpson DM, Brown S, Tobias JK, et al. NGX-4010, a capsaicin 8 % dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study. Clin J Pain. 2014;30(2):134–42.PubMedGoogle Scholar
  34. 34.••
    Brown S, Simpson DM, Moyle G, et al. NGX-4010, a capsaicin 8 % patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase II, randomized, controlled trials. AIDS Res Ther. 2013;10(1):5. An integrated analysis of two randomized control trials providing evidence that capsaicin transdermal 8 % patch significantly reduces pain in HIV-DSP.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Clifford DB, Simpson DM, Brown S, et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8 % dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr. 2012;59(2):126–33.PubMedCrossRefGoogle Scholar
  36. 36.
    Estanislao L, Carter K, McArthur J. A randomized controlled trial of 5 % lidocaine gel for HIV-assiociated distal symmetric polyneuropathy. J Acquir Immune Defic Syndr. 2004;37(5):1584–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Kieburtz K, Simpson D, Yiannoutsos C, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. Neurology. 1998;51:1682–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Harrison T, Lee A, et al. Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies. Pain Med. 2013;14(7):1039–47.PubMedCrossRefGoogle Scholar
  39. 39.
    Hahn K, Arendt G, Braun JS, et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol. 2004;251:1260–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Simpson DM, Schifitto G, Clifford DB. Pregabalin for painful HIV neuropathy: a randomized, double blind, placebo-controlled trial. Neurology. 2010;74(5):413–20.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Simpson DM, McArthur J, Olney R. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology. 2003;60:1508–14.PubMedCrossRefGoogle Scholar
  42. 42.
    Simpson DM, Olney R, McArthur JC, et al. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology. 2000;54(11):2115–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Simpson D, Dorfman D, Olney RK, et al. Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The peptide T neuropathy study group. Neurology. 1996;47(5):1254–9.Google Scholar
  44. 44.
    Gilron I, Bailey J, Dongsheng T, et al. Morphine, gabapentin, or their combination for neuropathic pain. NEJM. 2005;352:1324–34.PubMedCrossRefGoogle Scholar
  45. 45.
    Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo controlled trial. Neurology. 2007;68(7):515–21.PubMedCrossRefGoogle Scholar
  46. 46.
    Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34(3):672–80.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Youle M, Osio M, ALCAR Study Group. A double-blind, parallel-group, placebo-controlled, multicenter study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med. 2007;8(4):241–50.PubMedCrossRefGoogle Scholar
  48. 48.
    Valcour V, Yeh TM, Bartt R, et al. Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection. HIV Med. 2009;10(2):103–10.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Evans SR, Kitch DW, et al. A randomized trial evaluating prosapide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. PLoS One. 2007;2(6):e551.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    McArthur JC, Yiannoutsos C, Simpson DM, et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS clinical trials group team 291. Neurology. 2000;54(5):1080–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of NeurologyIcahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations